Table 5 Associations between PET/MRI quantitative parameters and clinicopathological characteristics

FIGO stage

 I

15.41 ± 6.88

0.90 ± 0.14

0.61 ± 0.13

17.36 ± 8.12

26.00 ± 12.07

 II

18.95 ± 4.67

0.84 ± 0.05

0.51 ± 0.10

22.52 ± 5.62

37.81 ± 9.79

    p-value

0.500

0.551

0.059

0.311

0.043*

 I

15.41 ± 6.88

0.90 ± 0.14

0.61 ± 0.13

17.36 ± 8.12

26.00 ± 12.07

 III

21.99 ± 7.77

0.79 ± 0.08

0.46 ± 0.06

28.17 ± 10.78

48.37 ± 15.75

    p-value

0.020*

0.021*

0.001*

0.001*

< 0.001*

 II

18.95 ± 4.67

0.84 ± 0.05

0.51 ± 0.10

22.52 ± 5.62

37.81 ± 9.79

 III

21.99 ± 7.77

0.79 ± 0.08

0.46 ± 0.06

28.17 ± 10.78

48.37 ± 15.75

    p-value

0.968

0.928

0.931

0.416

0.200

Histological type

 E

17.58 ± 7.52

0.88 ± 0.13

0.58 ± 0.12

20.56 ± 9.73

32.05 ± 15.66

 NE

15.20 ± 4.24

0.83 ± 0.10

0.49 ± 0.16

18.46 ± 6.01

32.98 ± 13.67

    p-value

0.389

0.335

0.084

0.558

0.875

Tumor grade

 G1 + G2

16.16 ± 7.13

0.89 ± 0.14

0.59 ± 0.14

18.71 ± 9.31

29.43 ± 15.51

 G3

19.78 ± 6.81

0.83 ± 0.08

0.52 ± 0.09

23.92 ± 8.38

38.65 ± 12.96

    p-value

0.082

0.048*

0.075

0.052

0.036*

Myometrial invasion depth

 < 50%

16.28 ± 7.66

0.89 ± 0.14

0.59 ± 0.14

18.99 ± 10.25

29.46 ± 15.80

 ≥ 50%

19.32 ± 5.63

0.84 ± 0.07

0.52 ± 0.08

23.03 ± 6.11

38.07 ± 12.57

    p-value

0.139

0.077

0.021*

0.128

0.047*

Cervical invasion

 Absent

16.47 ± 7.84

0.89 ± 0.14

0.60 ± 0.13

19.14 ± 10.17

28.96 ± 15.37

 Present

19.23 ± 4.73

0.84 ± 0.06

0.49 ± 0.09

23.13 ± 5.85

40.44 ± 11.88

    p-value

0.194

0.060

0.003*

0.147

0.010*

Metastatic pelvic lymph node

 Negative

16.37 ± 6.59

0.88 ± 0.13

0.58 ± 0.13

18.95 ± 8.07

29.67 ± 13.70

 Positive

22.56 ± 8.73

0.81 ± 0.08

0.48 ± 0.07

28.31 ± 12.56

47.53 ± 16.38

    p-value

0.022*

0.145

0.030*

0.007*

0.002*